TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03313453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PuriCare (HEPA Air Cleaner)
Description: The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mock device of PuriCare
Description: The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
Study: NCT02309060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Video Intervention (sTVi)
Description: Narrative communication, video-based intervention for depressed primary care patients.
Study: NCT04003220

Intervention type: PROCEDURE
Intervention: blood sample
Description: The extra samples will be taken Blood sampling

Intervention type: PROCEDURE
Intervention: blood sample
Description: The extra samples will be taken Blood sampling

Intervention type: PROCEDURE
Intervention: blood sample
Description: The extra samples will be taken Blood sampling

Intervention type: PROCEDURE
Intervention: Bone marrow sample
Description: This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls

Intervention type: PROCEDURE
Intervention: Bone marrow sample
Description: This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
Study: NCT00604864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti TNFa monoclonal antibody - Infliximab
Description: Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT03392025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed
Description: Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed
Description: Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the Mediterranean-like diet
Description: Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
Study: NCT00132613

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Observation alone after pericardial drainage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pericardial instillation of bleomycin after drainage
Study: NCT04800809

Intervention type: OTHER
Intervention: This study does not entail offering any intervention; all data collected will be based on standard of care.
Description: This study does not entail offering any intervention; all data collected will be based on standard of care.

Intervention type: OTHER
Intervention: This study does not entail offering any intervention; all data collected will be based on standard of care.
Description: This study does not entail offering any intervention; all data collected will be based on standard of care.
Study: NCT00705523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: 1.0 mg BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: BID 12 weeks
Study: NCT04493190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapular control training
Description: Participants in this group will learn how to maintain normal scapular position at first. Then they will progress to moving arm with good scapular control with mirror. Afterward, participants will undergo movements protocol which give different directions of arm movements while keeping scapula in a good alignment. They will also receive scapular-focused exercises. The difficulty of the movement protocol will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General exercise
Description: Participants in this group will receive a general shoulder strengthening with theraband or dumbbell. Load will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
Study: NCT00316134

Intervention type: PROCEDURE
Intervention: Procedure/Surgery
Description: Diagnostic and/or therapeutic procedure to remove pleural fluid.
Study: NCT03149471

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial dysfunction test
Description: The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial dysfunction test
Description: The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
Study: NCT01493648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (lactose 100 mg) for 3 months.
Study: NCT02803047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation number - SR15-61-Z15-034).
Study: NCT01504308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU treatment
Description: A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
Study: NCT02850211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
Study: NCT02422251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile high congruency bearing (Columbus)
Description: Columbus high congruency bearing on a rotating platform tibia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed high congruency bearing (Columbus)
Description: Columbus high congruency bearing on a fixed platform tibia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed high congruency bearing (Columbus)
Description: Columbus deep dish bearing on a fixed platform tibia.
Study: NCT02536703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Lotus Valve System
Study: NCT01562171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooked Lentils
Description: Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potato-Based Foods
Description: Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
Study: NCT02934022

Intervention type: DRUG
Group type: OTHER
Intervention: Maraviroc
Description: 150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
Study: NCT00567216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadolol
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Study: NCT00160355

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic stem cell transplantation
Description: To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.

Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi CliniMACS selection system
Description: This system depletes the hematopoietic stem cell graft of T and B lymphocytes.

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, Melphalan, Thiotepa
Description: Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
Study: NCT00730561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
Study: NCT00695253

Intervention type: DEVICE
Group type: OTHER
Intervention: Talent Endoluminal Spring Graft System
Description: Endovascular repair for patients with AAA who meet the inclusion criteria for the study
Study: NCT02099903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter renal denervation
Description: Renal sympathetic denervation with an irrigated radiofrequency catheter.
Study: NCT01690364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEP monitoring with continuous infusion of vecuronium during general anesthesia
Description: MEP monitoring with continuous infusion of vecuronium during general anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEP monitoring with continuous infusion of cisatracurium during general anesthesia
Description: MEP monitoring with continuous infusion of cisatracurium during general anesthesia
Study: NCT00617032

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^10 DNase resistant particles (DRP) / mL joint volume

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single dose 1x10\^11 DNase resistant particles (DRP) / mL joint volume

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: tgAAC94 placebo
Description: Single dose
Study: NCT00802009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivicaine
Description: Standard anesthetic solution administered during routine brachial plexus nerve blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivicaine
Description: Standard anesthetic solution administered during routine brachial plexus nerve blockade.
Study: NCT01071135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
Study: NCT00759330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tape (Arm 1)
Description: Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Tape (Arm 2)
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tape (Arm 3)
Description: Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Tape (Arm 4)
Description: Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
Study: NCT01050348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin calcium
Description: Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
Study: NCT01135706

Intervention type: OTHER
Intervention: No Intervention
Description: This study does not include an intervention but is observational in nature.

Intervention type: OTHER
Intervention: No Intervention
Description: This study does not include an intervention but is observational in nature.
Study: NCT04430465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grain products high in wholegrains from oat and rye
Description: A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grain products high in wholegrains from oat and rye
Description: A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grain products low in wholegrains
Description: A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grain products low in wholegrains
Description: A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
Study: NCT00842881

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Healingstone navel belt
Description: 6\~8hours/day for 3months

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Healingstone navel belt
Description: 6\~8hours/day for 3months
Study: NCT01633814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Description: transdermal estradiol, delivery rate 100 µg day-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo patch.
Study: NCT04251650

Intervention type: OTHER
Intervention: subgingival plaque sample
Description: for subgingival plaque sample, on three affected sites (PD\>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.

Intervention type: OTHER
Intervention: subgingival plaque sample
Description: for subgingival plaque sample, on three affected sites (PD\>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.

Intervention type: OTHER
Intervention: CGF sample
Description: each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites

Intervention type: OTHER
Intervention: CGF sample
Description: each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
Study: NCT02844049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: surgical procedure
Study: NCT01862133

Intervention type: OTHER
Intervention: Patient preferences
Description: Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
Study: NCT01975454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal therapy
Description: TLBZT based herbal decoction administered orally twice a day
Study: NCT01520896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: Oral 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NKTR-118
Description: Oral 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Oral 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Oral 400 mg
Study: NCT01210079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin;
Description: Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo titrated over 1 week with established dose taken daily for 5 weeks.
Study: NCT02804178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-101
Description: 125-1000 mg twice per week
Study: NCT02407184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newborn exposure to mother vaginal microbiota
Description: Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
Study: NCT03107650

Intervention type: PROCEDURE
Intervention: Transanal total mesorectal excision of rectal cancer
Description: To perform a total mesorectal excision through a transanal approach
Study: NCT03545776

Intervention type: OTHER
Intervention: Critical Care EEG Course
Description: Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG